van Tellingen O, Beijnen J H, Nooijen W J, Bult A
Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam.
Cancer Chemother Pharmacol. 1993;32(4):286-92. doi: 10.1007/BF00686174.
We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its metabolites in plasma, tissue, faeces and urine specimens. Pharmacokinetics studies were performed in male FVB mice receiving VBL by intravenous (i.v.) bolus injection at a dose of 6 mg/kg. Plasma concentrations were monitored until 48 h after drug administration. Urine and faeces samples were collected in 24-h portions for up to 72 h and tissue samples were obtained at 4, 24, 72 and 168 h after drug administration. To facilitate a comparison between the findings we obtained by high-performance liquid chromatography (HPLC) and the results of previous studies using radiolabeled drug monitoring, some of the animals were also given radiolabeled drug. Large discrepancies were observed between the results obtained by the two methods. Excretion of the radiolabel in faeces and urine was 85% of the dose within 72 h. HPLC revealed that only 18% of the dose was excreted as unchanged drug and 19%, as measurable metabolites [O4-deacetylvinblastine (DVBL) and two unknown compounds]. In most of the tissues taken at 4 h after drug administration, virtually all of the radioactivity represented VBL or DVBL. In all tissues taken at 72 h after drug administration, however, only very little of the radioactivity remained in the form of these compounds. Following the administration, VBL and DVBL were distributed extensively to most tissues. Many tissues appeared to possess effective means of extruding the cytotoxic drug with decreasing plasma levels. However, in some organs, including those from the genital tract and lymphatic tissues, VBL and DVBL were retained for prolonged periods. Our studies confirm previous indications that selective retention may be the basis of the activity of VBL against malignant transformations derived from these tissues.
我们开发并验证了一种基于离子交换正相液相色谱-荧光检测和液液萃取的选择性分析方法,用于分析生物基质中的长春碱(VBL)。该测定法适用于测定血浆、组织、粪便和尿液样本中的母体化合物及其代谢物。对雄性FVB小鼠进行了药代动力学研究,通过静脉推注以6 mg/kg的剂量给予VBL。监测血浆浓度直至给药后48小时。在给药后长达72小时内,每24小时收集一次尿液和粪便样本,并在给药后4、24、72和168小时获取组织样本。为便于比较我们通过高效液相色谱(HPLC)获得的结果与先前使用放射性标记药物监测的研究结果,部分动物也给予了放射性标记药物。两种方法获得的结果之间存在很大差异。7个2小时内粪便和尿液中放射性标记物的排泄量为剂量的85%。HPLC显示,仅18%的剂量以原形药物排泄,19%以可测量的代谢物[O4-去乙酰长春碱(DVBL)和两种未知化合物]排泄。在给药后4小时采集的大多数组织中,几乎所有放射性都代表VBL或DVBL。然而,在给药后72小时采集的所有组织中,只有极少部分放射性以这些化合物的形式存在。给药后,VBL和DVBL广泛分布于大多数组织。随着血浆水平降低,许多组织似乎具有有效排出细胞毒性药物的方式。然而,在一些器官中,包括生殖道和淋巴组织的器官,VBL和DVBL会被长时间保留。我们的研究证实了先前的迹象,即选择性保留可能是VBL对源自这些组织的恶性转化具有活性的基础。